Clinical Trials Browser

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

2,400 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04085276 2026-04-16

TORCHLIGHT

Phase 3 Completed

531 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

364 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Phase 3 Active not recruiting

1,155 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3 Recruiting

1,530 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06841354 2026-04-13

TroFuse-011

Phase 3 Recruiting

1,000 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04251533 2026-04-03

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Breast

Triple Negative Breast Neoplasms

NCT02445391 2026-04-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase 3 Active not recruiting

415 enrolled 15 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05806060 2026-03-25

BCTOP-T-M01

Phase 3 Recruiting

134 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

1,000 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms